High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer

被引:47
|
作者
Lin, Yang [1 ]
Lv, Feng [1 ]
Liu, Fangfang [1 ]
Guo, Xiaojing [1 ]
Fan, Yu [1 ]
Gu, Feng [1 ]
Gu, Jun [2 ,3 ]
Fu, Li [1 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab,Natl Clin Res C, Key Lab Breast Canc Prevent & Therapy,Minst Educ, Tianjin 300060, Peoples R China
[2] SUNY Albany, Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA
[3] SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 11期
基金
中国国家自然科学基金;
关键词
Pyruvate kinase M2; breast cancer chemosensitivity; epirubicin; 5-fluorouracil; DRUG-SENSITIVITY TEST; IN-VITRO; PKM2; CULTURE; CHEMOTHERAPY; RESISTANCE; CELLS; INHIBITION; PROGNOSIS; THERAPY;
D O I
10.7150/jca.12719
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pyruvate kinase M2 (PKM2) is the key enzyme in the Warburg effect, and it was recently reported to be involved in the metabolic pathways of chemotherapeutic drugs. However, the role of PKM2 in breast cancer and its influence in the sensitivity to front-line anticancer drugs remains unclear. Methods: In this study, we examined the correlation between the expression of PKM2 and the sensitivity of primary breast cancer cells to anticancer drugs. PKM2 expression was studied by immunohistochemistry using biopsy samples of 296 patients diagnosed with invasive breast carcinoma, and the collagen gel droplet embedded culture-drug sensitivity tests (CD-DST) was conducted to all the patients to detect in vitro chemosensitivity after surgery. Results: We found high PKM2 expression was significantly associated with in vitro chemosensitivity to epirubicin (EPI) (P=0.019) and 5-fluorouracil (5-Fu) (P=0.009) in breast cancer patients. Then we used a small group of neoadjuvant chemotherapy cases to confirm that the higher PKM2 expression, the better pathological response to therapy was obtained in patients treated with EPI-based or EPI plus 5-Fu chemotherapy regimens. Although univariate and multivariate analysis indicated that high PKM2 was a poor independent predictor of progression free survival (PFS) and overall survival (OS) in breast cancer, patients with PKM2 high expression who received EPI-based or EPI plus 5-Fu chemotherapy were found to have a longer PFS (P=0.003, P=0.013) and OS (P=0.003, P=0.004) than patients treated with non-EPI/5-Fu-based regimens, respectively. Conclusions: Our findings confirmed the poor prognosis of high PKM2 expression in breast cancer patients and revealed the predictive value of high PKM2 in the therapeutic response to EPI and 5-Fu. Moreover, our results provide the guidance of individual treatment for breast cancer patients who are foreboded a poor prognosis by the presence of high PKM2 status.
引用
收藏
页码:1130 / 1139
页数:10
相关论文
共 50 条
  • [31] Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer
    Tan, Wen Lee
    Bhattacharya, Bhaskar
    Loh, Marie
    Balasubramanian, Indirikumar
    Akram, Mohamed
    Dong, Difeng
    Wong, Limsoon
    Thakkar, Bhavin
    Salto-Tellez, Manuel
    Soo, Ross A.
    Fichtner, Iduna
    Iacopetta, Barry
    Soong, Richie
    CANCER BIOLOGY & THERAPY, 2011, 11 (06) : 599 - 608
  • [32] COMBINED EPIRUBICIN, EPIRUBICIN, 5-FLUOROURACIL AND FOLINIC ACID WITH ALLOPURINOL PROTECTION FOR 2ND-LINE TREATMENT OF ADVANCED GASTRIC-CANCER - A PILOT-STUDY
    TSAVARIS, N
    MYLONAKIS, N
    BACOYIANNIS, C
    PAPASTRATIS, G
    KATSIKAS, M
    PAPADIMITRAKOPOULOU, V
    MACHERAS, A
    STAMELOU, A
    KOSMIDIS, P
    ONKOLOGIE, 1995, 18 (04): : 346 - 350
  • [33] Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis
    Huang, Changkun
    Huang, Zhichao
    Bai, Peiming
    Luo, Guangcheng
    Zhao, Xiaokun
    Wang, Xinjun
    ONCOTARGETS AND THERAPY, 2018, 11 : 2075 - 2082
  • [34] A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
    Jinno, H.
    Sakata, M.
    Hayashida, T.
    Takahashi, M.
    Mukai, M.
    Ikeda, T.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1262 - 1266
  • [35] M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling
    Wei, Chen
    Yang, Chaogang
    Wang, Shuyi
    Shi, Dongdong
    Zhang, Chunxiao
    Lin, Xiaobin
    Xiong, Bin
    ONCOTARGETS AND THERAPY, 2019, 12 : 3051 - 3063
  • [36] Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
    Apostolidi, Maria
    Vathiotis, Ioannis A.
    Muthusamy, Viswanathan
    Gaule, Patricia
    Gassaway, Brandon M.
    Rimm, David L.
    Rinehart, Jesse
    CANCER RESEARCH, 2021, 81 (16) : 4346 - 4359
  • [37] Tumor pyruvate kinase M2: A promising molecular target of gastrointestinal cancer
    Guo, Chen
    Li, Guan
    Hou, Jianing
    Deng, Xingming
    Ao, Sheng
    Li, Zhuofei
    Lyu, Guoqing
    CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (06) : 669 - 676
  • [38] Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2
    Wei, Lan
    Li, Kuangfa
    Pang, Xueli
    Guo, Bianqin
    Su, Min
    Huang, Yunxiu
    Wang, Nian
    Ji, Feihu
    Zhong, Changli
    Yang, Junhong
    Zhang, Zhiqian
    Jiang, Yulin
    Liu, Yifeng
    Chen, Tingmei
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [39] Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2
    Babu, Mani Shankar
    Mahanta, Sailendra
    Lakhter, Alexander J.
    Hato, Takashi
    Paul, Subhankar
    Naidu, Samisubbu R.
    PLOS ONE, 2018, 13 (02):
  • [40] Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
    Zahra, Kulsoom
    Dey, Tulika
    Ashish
    Mishra, Surendra Pratap
    Pandey, Uma
    FRONTIERS IN ONCOLOGY, 2020, 10